HCW Biologics (HCWB) Research & Development (2020 - 2025)
HCW Biologics' (HCWB) quarterly Research & Development came in at $1.3 million in Q4 2025, up 126.94% YoY from $587435.6 in Q4 2024, and down 5.07% on a QoQ basis from $1.4 million in Q3 2025.
HCW Biologics (HCWB) Research & Development (2020 - 2025) Analysis & Trends
HCW Biologics (HCWB) has 6 years of Research & Development data on file, last reported at $1.3 million in Q4 2025.
- Quarterly Research & Development rose 126.94% year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.4 million (up 1294.86% YoY) and the FY2025 annual result came in at $5.4 million, up 1294.86% from the prior year.
- Research & Development fell to $1.3 million in Q4 2025, from $1.4 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $2.7 million in Q3 2021 to a low of -$6.0 million in Q4 2022.
- A 5-year average of $749504.8 and a median of $1.6 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development plunged 502.25% — and 2025, when it surged 126.94%.
- Tracing HCWB's Research & Development over 5 years: stood at $1.5 million in 2021, then sank by 502.25% to -$6.0 million in 2022, then gained by 16.23% to -$5.0 million in 2023, then grew by 0.98% to -$4.9 million in 2024, then surged by 126.94% to $1.3 million in 2025.
- The last three Research & Development figures came in at $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.2 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | HCW Biologics | 2.86 Mn | 2.11 Mn | -93,887.00 | 1.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.33 Mn |
| Sep 30, 2025 | 1.40 Mn |
| Jun 30, 2025 | 1.23 Mn |
| Mar 31, 2025 | 1.48 Mn |
| Dec 31, 2024 | -4.95 Mn |
| Sep 30, 2024 | 1.19 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 2.12 Mn |
| Dec 31, 2023 | -5.00 Mn |
| Sep 30, 2023 | 1.67 Mn |
| Jun 30, 2023 | 1.62 Mn |
| Mar 31, 2023 | 2.26 Mn |
| Dec 31, 2022 | -5.97 Mn |
| Sep 30, 2022 | 2.65 Mn |
| Jun 30, 2022 | 1.97 Mn |
| Mar 31, 2022 | 1.79 Mn |
| Dec 31, 2021 | 1.48 Mn |
| Sep 30, 2021 | 2.69 Mn |
| Jun 30, 2021 | 1.67 Mn |
| Mar 31, 2021 | 2.33 Mn |